SYS-CON MEDIA Authors: Jason Bloomberg, Kevin Benedict, David H Deans, RealWire News Distribution, Gilad Parann-Nissany

News Feed Item

The Market and Potential for Molecular Point of Care Diagnostics

NEW YORK, March 25, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Market and Potential for Molecular Point of Care Diagnostics
http://www.reportlinker.com/p02051940/The-Market-and-Potential-for-Molecular-Point-of-Care-Diagnostics.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

The molecular diagnostic market and the point-of-care (POC) testing markets are two of the fastest growing segments of the overall IVD market. Historically, these have been completely different market segments. Not anymore. There has been a growing interest in developing molecular diagnostic platforms that can be used in POC settings. Indeed, as this new market research report from Kalorama Information details, the emerging area of rapid molecular POC testing has attracted over $650 million in investments and financings over the past five years (2009 to 2013).

This report, The Market and Potential for Molecular Point of Care Diagnostics, offers a quantitative assessment of the molecular diagnostic market, and of the point-of-care (POC) testing market, and then looks at the emerging field of molecular diagnostic POC testing. Many companies are developing molecular diagnostic platforms and assays that are designed to for near-patient or POC testing, and the earliest of these systems are starting to reach the market. The initial market focus for most of these companies is on infectious disease testing, where rapid test results generate important actionable information that physicians can use to make treatment decisions.

Superior Data For Business Planning

As part of this coverage, the report provides:

• Profiles of Molecular POC Companies and Products
• Market Estimates for Molecular Diagnostics and POC Diagnostics 2013-2018
• Investments and Financing Agreements for POC Molecular
• Infectious Disease Diagnostics Opportunities
• Agreements Between with Other Diagnostic Companies
• Acquisitions of Molecular Diagnostic Near-Patient/Point-of-Care Companies
• Investor Spending in Molecular POC
• Deals Made Recently in Point of Care
• Profiles of Key Companies in the Market

Advances in molecular diagnostic technologies, combined with advances in microfluidics and other instrumentation technologies, are making it possible to develop new platforms and tests that meet the needs of a true POC system. Platforms for molecular diagnostic POC testing need to be small, portable, potentially hand-held, easy-to-use, and inexpensive. They need to be fully automated from sample to answer, so that they can be used by individuals who are not highly trained in molecular diagnostics or in laboratory testing in general.

Detailed Lists of Companies, Products, Recent Deals

Market analyses in this report cover world markets for molecular diagnostic point of care tests. However, the reader will find a bias toward the developed areas of the globe -- North America, Japan and Western Europe. Yet, it is important to remember that health and infectious disease are a growing global problem. Molecular diagnostic point-of-care tests represent an important aspect of bringing healthcare limited resource settings, and some sections of this report specifically focus on these activities. Market data in this report are based on factory sales to the end user, and not on retail pricing or reimbursement payments.

The information presented in this report is derived from publicly available information sources such as company reports and announcements, government reports and databases, medical organization reports, medical associations, and other publications. The analysis is based on the author's industry knowledge combined with literature searches and discussions with industry professionals and experts in the areas of point-of-care tests, decentralized healthcare and healthcare economics.

Over 75 companies involved in this market are profiled in this report. As expected with any group of start-up companies, many are struggling or are surviving on limited financial resources. However, some new companies that are focusing on molecular diagnostic POC testing have received significant investments.
CHAPTER ONE: EXECUTIVE SUMMARY
Overview
Scope and Methodology
Market Overviews –Molecular Diagnostic and Point-of-Care Markets
Future Prospects –Molecular DIAGNOSTIC NEAR Patient/Point-of-Care Testing
CHAPTER TWO: INTRODUCTION
Evolution Towards Point-of-Care in Molecular Diagnostics – Market Drivers
Patent focused drivers
Medical/Healthcare related drivers
Technology drivers
Economic drivers
Other drivers

Overview of Companies Developing
Rapid Point-of-Care/Near-Patient Molecular Diagnostics Platforms
Point of View
CHAPTER THREE: ADVANCES IN MOLECULAR DIAGNOSTIC TECHNOLOGY
Molecular Diagnostic Technology Today
Advances and Emerging New Technologies to Make
POC Testing Possible
Advancing Molecular Diagnostic Technology for Limited Resource Settings – Non-Profit
Organizations
Bill & Melinda Gates Foundation (BMGF)
Foundation for Innovative New Diagnostics (FIND)
Program for Appropriate Technology in Health (PATH)
UNITAID
CHAPTER FOUR: DEALS – COMPANIES TARGETING MOLECULAR POINT-OF NEED/POINT-OF-CARE
Investments and Financing Agreements for Molecular Diagnostic Near-Patient/Point-of-Care
Companies
Agreements Between with Other Diagnostic Companies
Acquisitions of Molecular Diagnostic Near-Patient/Point-of-Care Companies
CHAPTER FIVE: CURRENT MARKETS

Molecular Diagnostics Market Overview
Point-of Care-Market Overview
Emerging Molecular Diagnostics Point-of-Care Market
CHAPTER SIX: MARKET OPPORTUNITIES
Healthcare Associated Infections
Influenza and Other Respiratory Tract Infections
Sexually Transmitted Diseases
Sepsis
Selected Infectious Diseases in Developing Countries
HIV/AIDS
Tuberculosis
Malaria Selected Other Diseases Found in Developing Countries
Other Infectious Diseases
Hematology/Oncology
Pharmacogenomic Tests
Risk of Thrombosis
Warfarin Sensitivity
CYP2C19 Genotyping
CHAPTER SEVEN: TECHNOLOGY DEVELOPMENTS AND PROGRESS TO DATE
Progress to Date and Current Trends
Issues and Hurdles Faced by Companies Developing Molecular Diagnostic POC Tests and
Platforms
Future Prospects
CHAPTER EIGHT: COMPANY PROFILES

Abacus Diagnostica Oy
Access Bio, Inc.
Ahram Biosystems, Inc.
Akers Biosciences, Inc.
Akonni Biosystems, Inc.
Alere Inc.
Amplino
Analytik Jena AG
Aquila Diagnostic Systems Inc.
Atlas Genetics Ltd
Atonomics A/S
Axxin
BD Diagnostics
Biocartis SA
BioFire Diagnostics, Inc.
bioMérieux sa
Canon U.S. Life Sciences
Cepheid
Coris BioConcept
Curetis AG

DestiNA Genomics Ltd.
Diagnostics for All (DFA)
Diagnostics for the Real World, Ltd.
DiaSorin S.p.A.
DiAssess Inc
DNA Electronics Ltd.
DxNA, LLC
Eiken Chemical Co., Ltd.
Enigma Diagnostics Limited
Epistem
Espira, Inc.
Focus Diagnostics, Inc.
GeneFluidics, Inc.
GenePOC Inc.
Great Basin Corporation
Hai Kang Life Corporation Limited
Hain Lifescience GmbH
HiberGene Diagnostics Ltd

iCubate, Inc.
Immunexpress Group
InstantLabs
Instrumentation Laboratory
IQuum, Inc.
Life Technologies Corporation
LiquiLume Diagnostics, Inc.
Lumora Ltd
Mast Group Ltd.
MBio Diagnostics, Inc.
Meridian Bioscience, Inc.
Mesa Tech International, Inc.
Metaara Medical Technologies Inc.
Micronics Inc. (A Sony Group Company)
Molbio Diagnostics Pvt. Ltd.
MP Biomedicals, LLC
MycroLab Diagnostics Pty Ltd.
Nanobiosym (NBS)
Nanobiosym Diagnostics (NBSDx)
NanoBioSys Inc.
NanoDetection Technology, Inc. (NDT)
NanoIVD, Inc.
Nanomix, Inc
Nanosphere, Inc.
NetBio, Inc.
NorChip
OptiGene Ltd.
PositiveID Corporation

QIAGEN N.V
QuantuMDx Group
Quidel Corporation
Rheonix Inc.
SA Scientific
Seegene, Inc.
Spartan Bioscience Inc.
STAT-Diagnostica
T2 Biosystems, Inc
Thermal Gradient, Inc.
TwistDx, Ltd. (Acquired by Alere)
Ustar Biotechnologies (Hangzhou) Ltd.
Veredus Laboratories Pte Ltd
Wave 80 Biosciences

To order this report: The Market and Potential for Molecular Point of Care Diagnostics
http://www.reportlinker.com/p02051940/The-Market-and-Potential-for-Molecular-Point-of-Care-Diagnostics.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.